{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T01:46:21Z","timestamp":1776995181153,"version":"3.51.4"},"reference-count":36,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Infections with cytomegalovirus (CMV) are one of the most frequent opportunistic infections in kidney transplant recipients. Current risk-adapted CMV chemoprophylaxis regimens are based almost solely on the donor and recipient CMV serostatus. Of note, the NFKB1 -94ins\/delATTG promoter polymorphism was recently associated with a higher risk of CMV infection. Since single genetic association studies suffer from poor reliability for drawing therapeutic implications, we performed this confirmatory study and included 256 kidney transplant recipients from 2007 to 2014 in this retrospective study. Patients were genotyped for the -94ins\/delATTG NFKB1 promoter polymorphism and followed up for 12 months. The incidence of CMV infection within 12 months after kidney transplantation was 37.5% (33\/88) for the ins\/ins, 21.5% (28\/130) for the ins\/del, and 23.7% (9\/38) for the del\/del genotypes (p = 0.023). Moreover, we evaluated the time of CMV infection onset. Ins\/ins carriers had primarily late-onset CMV infection (median 194 days; interquartile range (IQR) 117\u2013267 days) compared with heterozygous (ins\/del; median 158 days; IQR 82\u2013195 days) and homozygous deletion allele carriers (del\/del; median 95 days; 84\u2013123 days). Multivariate-restricted Cox regression model confirmed the ins\/ins genotype to be an independent risk factor for the development of late-onset CMV infections. These findings should have an impact on post-kidney transplantation CMV chemoprophylaxis regimens.<\/jats:p>","DOI":"10.3390\/cells10020380","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T18:45:00Z","timestamp":1613155500000},"page":"380","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The NFKB1 Promoter Polymorphism (-94ins\/delATTG) Is Associated with Susceptibility to Cytomegalovirus Infection after Kidney Transplantation and Should Have Implications on CMV Prophylaxis Regimens"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6509-1463","authenticated-orcid":false,"given":"Hartmuth","family":"Nowak","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Knappschaftskrankenhaus Bochum, Ruhr-University Bochum, In der Schornau 23-25, 44892 Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svenja","family":"Vornweg","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Knappschaftskrankenhaus Bochum, Ruhr-University Bochum, In der Schornau 23-25, 44892 Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Rump","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Knappschaftskrankenhaus Bochum, Ruhr-University Bochum, In der Schornau 23-25, 44892 Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7039-6288","authenticated-orcid":false,"given":"Tim","family":"Rahmel","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Knappschaftskrankenhaus Bochum, Ruhr-University Bochum, In der Schornau 23-25, 44892 Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1500-1984","authenticated-orcid":false,"given":"Matthias","family":"Unterberg","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Knappschaftskrankenhaus Bochum, Ruhr-University Bochum, In der Schornau 23-25, 44892 Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Koos","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Knappschaftskrankenhaus Bochum, Ruhr-University Bochum, In der Schornau 23-25, 44892 Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Schenker","sequence":"additional","affiliation":[{"name":"Department of Surgery, University Hospital Knappschaftskrankenhaus Bochum, Ruhr-University Bochum, In der Schornau 23-25, 44892 Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Viebahn","sequence":"additional","affiliation":[{"name":"Department of Surgery, University Hospital Knappschaftskrankenhaus Bochum, Ruhr-University Bochum, In der Schornau 23-25, 44892 Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Adamzik","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Knappschaftskrankenhaus Bochum, Ruhr-University Bochum, In der Schornau 23-25, 44892 Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8603-8549","authenticated-orcid":false,"given":"Lars","family":"Bergmann","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Knappschaftskrankenhaus Bochum, Ruhr-University Bochum, In der Schornau 23-25, 44892 Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1056\/NEJM199806113382407","article-title":"Infection in organ-transplant recipients","volume":"338","author":"Fishman","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/TP.0b013e31829df29d","article-title":"Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"96","author":"Kotton","year":"2013","journal-title":"Transplantation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1097\/01.tp.0000230460.42558.b0","article-title":"The natural course of cytomegalovirus infection and disease in renal transplant recipients","volume":"82","author":"Hartmann","year":"2006","journal-title":"Transplantation"},{"key":"ref_4","unstructured":"Gjertson, D.W. (2003). Look-up survival tables for living-donor renal transplants: OPTN\/UNOS data 1995-2002. Clin. Transpl., 337\u2013386. Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/15387123\/."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/tri.12629","article-title":"Cytomegalovirus post kidney transplantation: Prophylaxis versus pre-emptive therapy?","volume":"28","author":"Fehr","year":"2015","journal-title":"Transpl. Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/TP.0b013e318238dab3","article-title":"Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial","volume":"93","author":"Witzke","year":"2012","journal-title":"Transplantation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1111\/j.1600-6143.2006.01413.x","article-title":"Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients","volume":"6","author":"Khoury","year":"2006","journal-title":"Am. J. Transplant."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-6143.2007.02031.x","article-title":"Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation","volume":"8","author":"Reischig","year":"2008","journal-title":"Am. J. Transplant."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/ajt.13107","article-title":"Association between individual and combined SNPs in genes related to innate immunity and incidence of CMV infection in seropositive kidney transplant recipients","volume":"15","author":"Corrales","year":"2015","journal-title":"Am. J. Transplant."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.3389\/fimmu.2019.02871","article-title":"The Aquaporin 5 -1364A\/C Promoter Polymorphism Is Associated With Cytomegalovirus Infection Risk in Kidney Transplant Recipients","volume":"10","author":"Rahmel","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Ono, G., Medina Pestana, J.O., and Aranha Camargo, L.F. (2019). Late cytomegalovirus (CMV) infections after kidney transplantation under the preemptive strategy: Risk factors and clinical aspects. Transpl. Infect. Dis., 21.","DOI":"10.1111\/tid.13035"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1101\/gad.183434.111","article-title":"NF-kappaB, the first quarter-century: Remarkable progress and outstanding questions","volume":"26","author":"Hayden","year":"2012","journal-title":"Genes Dev."},{"key":"ref_13","first-page":"104","article-title":"Modulation of the NFkappab Signalling Pathway by Human Cytomegalovirus","volume":"1","author":"Hancock","year":"2017","journal-title":"Virology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/wsbm.1331","article-title":"Signaling via the NFkappaB system","volume":"8","author":"Mitchell","year":"2016","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1146\/annurev.immunol.021908.132641","article-title":"Regulation and function of NF-kappaB transcription factors in the immune system","volume":"27","author":"Vallabhapurapu","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00134-007-0649-4","article-title":"Insertion\/deletion polymorphism in the promoter of NFKB1 influences severity but not mortality of acute respiratory distress syndrome","volume":"33","author":"Adamzik","year":"2007","journal-title":"Intensive Care Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1399-0039.2010.01559.x","article-title":"Association of NFKB1 -94ins\/delATTG promoter polymorphism with susceptibility to autoimmune and inflammatory diseases: A meta-analysis","volume":"77","author":"Zou","year":"2011","journal-title":"Tissue Antigens"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Schafer, S.T., Gessner, S., Scherag, A., Rump, K., Frey, U.H., Siffert, W., Westendorf, A.M., Steinmann, J., Peters, J., and Adamzik, M. (2014). Hydrocortisone fails to abolish NF-kappaB1 protein nuclear translocation in deletion allele carriers of the NFKB1 promoter polymorphism (-94ins\/delATTG) and is associated with increased 30-day mortality in septic shock. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0104953"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"58659","DOI":"10.18632\/oncotarget.10808","article-title":"An updated meta-analysis of 37 case-control studies on the association between NFKB1 -94ins\/del ATTG promoter polymorphism and cancer susceptibility","volume":"7","author":"Luo","year":"2016","journal-title":"Oncotarget"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Leone, F., Gigliotti, P., La Russa, A., Lofaro, D., Perri, A., Vizza, D., Lupinacci, S., Toteda, G., Bonofiglio, M., and Presta, P. (2019). NFKB1 promoter polymorphism: A new predictive marker of cytomegalovirus infection after kidney transplantation. Transpl. Infect. Dis., 21.","DOI":"10.1111\/tid.13027"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7150\/ijms.8.492","article-title":"Translational medicine and reliability of single-nucleotide polymorphism studies: Can we believe in SNP reports or not?","volume":"8","author":"Valachis","year":"2011","journal-title":"Int. J. Med. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_23","unstructured":"Fryer, J.F., Heath, A.B., Anderson, R., Minor, P.D., and World Health Organization Biologicals Unit (2020, June 18). Collaborative Study to Evaluate the Proposed 1st [first] WHO International Standard for Human Cytomegalovirus (HCMV) for Nucleic Acid Amplification (NAT)-Based Assays. Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/70521."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1523-1755.1999.00299.x","article-title":"The Banff 97 working classification of renal allograft pathology","volume":"55","author":"Racusen","year":"1999","journal-title":"Kidney Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/tri.12737","article-title":"Biopsy-proven acute cellular rejection as an efficacy endpoint of randomized trials in liver transplantation: A systematic review and critical appraisal","volume":"29","author":"Tsochatzis","year":"2016","journal-title":"Transpl. Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1600-6143.2004.00382.x","article-title":"Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients","volume":"4","author":"Paya","year":"2004","journal-title":"Am. J. Transplant."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"10","author":"Humar","year":"2010","journal-title":"Am. J. Transplant."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/jmv.23539","article-title":"High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy","volume":"85","author":"Harvala","year":"2013","journal-title":"J. Med. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1086\/528718","article-title":"Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation","volume":"46","author":"Arthurs","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.virol.2005.09.065","article-title":"Prolonged activation of NF-kappaB by human cytomegalovirus promotes efficient viral replication and late gene expression","volume":"346","author":"DeMeritt","year":"2006","journal-title":"Virology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1128\/JVI.78.9.4498-4507.2004","article-title":"Activation of the NF-kappaB pathway in human cytomegalovirus-infected cells is necessary for efficient transactivation of the major immediate-early promoter","volume":"78","author":"DeMeritt","year":"2004","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1073\/pnas.90.3.1107","article-title":"Multiple mechanisms are implicated in the regulation of NF-kappa B activity during human cytomegalovirus infection","volume":"90","author":"Kowalik","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"11686","DOI":"10.1128\/JVI.01168-06","article-title":"Human cytomegalovirus blocks tumor necrosis factor alpha- and interleukin-1beta-mediated NF-kappaB signaling","volume":"80","author":"Montag","year":"2006","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1128\/JVI.00060-06","article-title":"Human cytomegalovirus attenuates interleukin-1beta and tumor necrosis factor alpha proinflammatory signaling by inhibition of NF-kappaB activation","volume":"80","author":"Jarvis","year":"2006","journal-title":"J. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/ALN.0b013e318277a652","article-title":"The NFKB1 promoter polymorphism (-94ins\/delATTG) alters nuclear translocation of NF-kappaB1 in monocytes after lipopolysaccharide stimulation and is associated with increased mortality in sepsis","volume":"118","author":"Adamzik","year":"2013","journal-title":"Anesthesiology"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Liu, T., Zhang, L., Joo, D., and Sun, S.C. (2017). NF-kappaB signaling in inflammation. Signal Transduct. Target. Ther., 2.","DOI":"10.1038\/sigtrans.2017.23"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/2\/380\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:23:21Z","timestamp":1760160201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/2\/380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,12]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["cells10020380"],"URL":"https:\/\/doi.org\/10.3390\/cells10020380","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,12]]}}}